Trial Profile
An Open-Label, Long-Term Safety and Tolerability Study of RBP-7000 in the Treatment of Subjects With Schizophrenia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 31 Jul 2019
Price :
$35
*
At a glance
- Drugs Risperidone (Primary) ; Risperidone (Primary)
- Indications Schizophrenia
- Focus Adverse reactions; Registrational
- Sponsors Indivior; Reckitt Benckiser
- 23 Jul 2019 Results published in the Journal of Clinical Psychopharmacology
- 14 Nov 2018 Results presented at the 21st Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
- 09 May 2018 Results assessing safety and efficacy from two phase III trials (NCT02109562 and NCT02203838) presented at the 171st Annual Meeting of the American Psychiatric Association